$CELZ loves to run! GET READY FRIENDS!
$CELZ is a volume leader in the OTCQB
$CELZ is 100% compliant and timely with all SEC filings
$CELZ is an A-Rated SEC OTCQB company
$CELZ ran from $0.002 in march of last year to $0.07 this June!
$CELZ is a commercial stage Bio-technology company with many patents
$CELZ is just in the early phases of commercializing its first patent
$CELZ is domestically and internationally marketing CaverStem TM
$CELZ Company formed the subsidiary CaverStem International LLC for the purpose of commercializing its erectile dysfunction technology to international physicians.
$CELZ has CaverStem™ which received positive reception at international urology conference. Russia was just a start...Switzerland, France, Italy, UAE, and more are about to come on line-get ready.
$CELZ will have Approximately 30% of the 30,000,000 patients in the United States suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the muscles, blood vessels, and nerves needed to achieve erections.
$CELZ flagship CaverStem has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is booming! According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023.
All information from DD and recent Microcaps unsolicited article-available upon request!
My research and my opinion. My opinions is not a recommendation to buy or sell a security. Your decision whether or not to make a purchase should be based on your own due diligence.
